Nickel–quinolones interaction. Part 1 – Nickel(II) complexes with the antibacterial drug sparfloxacin: Structure and biological properties

Skyrianou, Kalliopi C.; Efthimiadou, Eleni K.; Psycharis, Vassilis; Terzis, Aris; Kessissoglou, Dimitris P.; Psomas, George

doi:10.1016/j.jinorgbio.2009.08.011

Cited by 108 publications

(94 citation statements)

References 62 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many therapeutic agents, particularly anticancer drugs, are known to bind DNA via either of these motifs and the possibility of gene modulation by specific sequence binding of small molecules to DNA has also been explored. The interaction of Ni(II) complexes with DNA has been mainly dependent on the structure of the ligand exhibiting intercalative behavior [19][20][21][22][23] and/or DNA cleavage ability. 24,25 Serum albumin is the major soluble protein constituent in the circulatory system of a wide variety of organisms and it has the ability to reversibly bind to a large variety of endogenous and exogenous ligands such as fatty acids, drugs, and metal ions in the bloodstream.…”

Section: Introductionmentioning

confidence: 99%

Variation in the biomolecular interactions of nickel(ii) hydrazone complexes upon tuning the hydrazide fragment

et al. 2012

View full text Add to dashboard Cite

3 )] (6). Structural characterization of these compounds 4-6 were accomplished by using various physico-chemical techniques. Single crystal X-ray diffraction data of complexes 4 and 5 proved their distorted square planar geometry. In order to ascertain the potential of the above synthesised compounds towards biomolecular interactions, additional experiments involving interaction with calf thymus DNA (CT DNA) and bovine serum albumin (BSA) were carried out. All the ligands and corresponding nickel(II) chelates have been screened for their scavenging effect towards O 2 − , OH and NO radicals. The efficiency of complexes 4-6 to arrest the growth of HeLa, HepG-2 and A431 tumour cell lines has been studied along with the cell viability test against the non-cancerous NIH 3T3 cells under in vitro conditions.

show abstract

Section: Introductionmentioning

confidence: 99%

Variation in the biomolecular interactions of nickel(ii) hydrazone complexes upon tuning the hydrazide fragment

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The hypochromism or decrease in absorption intensity of the compound 1 observed on gradual addition of CT DN A (0.00-6.50 × 10 -5 mol L -1 ) to its fixed concentration(1.11 × 10 -4 mol L -1 ) (Figure 4), was attributed to interaction of its π* molecular orbitals with the π-orbitals of the DNA base pairs, resulting in a decreased π-π* transition probability and hence hypochromism. [22] The binding constant Kb quantifying binding propensity of compound 1 with CT DNA, was obtained from the change in the absorbance spectra with increasing concentrations of CT DNA. The binding constant of 7.24 × 10 4 mol L -1 was calculated from the ratio of slope to the intercept in the inset plot of ( Figure 4) using Wolfee-Shimmer equation.…”

Section: Dna Binding Studies Absorption Spectral Studiesmentioning

confidence: 99%

Synthesis, Crystal Structure and in vitro DNA Binding Studies of Combretastatin A-4 Analogue

Rizvi¹,

Dangat²,

Yaseen³

et al. 2015

Croat. Chem. Acta

View full text Add to dashboard Cite

Synthesis of a novel Combretastatin A-4 analogue using Schiff's reaction of benzil and 4-aminoantipyrine has been achieved under solvent free conditions. The structure of compound was examined spectroscopically and confirmed from single crystal diffraction studies. The synthesized Combretastatin A-4 analogue was investigated for its DNA binding ability as the plausible mechanism for its antitumor activity. The binding propensity of the synthesized compound with calf-thymus (CT) DNA was monitored with absorption and emission spectrophotometric titrations. The calculations predict a binding constant of 7.24 × 10 4 for the complex of the synthesized compound with CT DNA which is comparable in magnitude to that of DNA binding of bactericidal drug enoxacin and typical intercalation indicator ethidium bromide (EB). Competitive binding studies of the synthesized compound with EB using fluorescence titration reveal that it displaces the DNA-bound EB and binds in intercalative mode which was further supported by circular dichroism (CD) spectroscopy. The probable site and binding energy of the compound with DNA was further theoretically investigated by molecular docking studies. The significant DNA binding ability of the synthesized Combretastatin A4 analogue as revealed from this study could be related to the anticancer activity of the Combretastatin A4.

show abstract

“…The reduction of metals below certain limit results consistently in a reduction of physiologically important function (11) . Although, the absorption of quinolone drugs is lowered when they are administered simultaneously with multivitamins, magnesium or aluminium containing antacids and others cations (12,13) , the proposed mechanism of the interaction is chelation between the 4-oxo and adjacent carboxyl group of quinolone and metal cations (10,(14)(15)(16) . Since these functional groups are required for antibacterial activity, it could be anticipated that all of the quinolones could be interacting with metal ions (15) .…”

Section: Fig1 Structure Of Moxifloxacinmentioning

confidence: 99%

Synthesis, Characterization, Spectrofluorometric and Antibacterial Activity Studies of Moxifloxacin- Zirconium Complex

2012

Egypt. J. Chem.

View full text Add to dashboard Cite

PECTROSCOPIC methods such as mass, FT-IR and nuclear ........magnetic resonance in combination with thermal analysis measurements were used to verify and describe the physicochemical properties of the synthesized moxifloxacin (MOX) Zirconium (IV) metal complex. The spectroscopic and elemental analysis data support the formation of the complex with the formula C 21 H 23 FN 3 O 4 Zr(H 2 O) 2 .0.5H 2 O. Results revealed that complexation between Zirconium (IV) and moxifloxacin exhibited significant increase in antibacterial activity especially against Gram negative organisms.In addition, a simple, rapid, reliable, and sensitive spectrofluorometric method is developed for the determination of MOX. The method depends on the chelation of MOX with zirconium (IV) to produce fluorescent chelate (MOX/ Zr). Different factors affecting the relative fluorescence intensity of the resulting chelate were studied and optimized. The relationship between the concentration and relative fluorescence intensity was rectilinear in the range of 0.1-4 µg/ml. The limits of detection and quantitation are 0.06 and 0.11 µg/ ml, respectively.At the optimum reaction conditions, the drug-metal chelate showed excitation maximum at 333 nm and emission maxima at 485nm. The developed method was applied successfully for the determination of the studied drug in its pharmaceutical dosage forms with a good precision and accuracy.

show abstract

Nickel–quinolones interaction. Part 1 – Nickel(II) complexes with the antibacterial drug sparfloxacin: Structure and biological properties

Cited by 108 publications

References 62 publications

Variation in the biomolecular interactions of nickel(ii) hydrazone complexes upon tuning the hydrazide fragment

Variation in the biomolecular interactions of nickel(ii) hydrazone complexes upon tuning the hydrazide fragment

Synthesis, Crystal Structure and in vitro DNA Binding Studies of Combretastatin A-4 Analogue

Synthesis, Characterization, Spectrofluorometric and Antibacterial Activity Studies of Moxifloxacin- Zirconium Complex

Contact Info

Product

Resources

About